Literature DB >> 23483648

Intensity-modulated radiotherapy followed by a brachytherapy boost for oropharyngeal cancer.

Abrahim Al-Mamgani1, Peter C Levendag, Peter van Rooij, Cees A Meeuwis, Aniel Sewnaik, David N Teguh.   

Abstract

BACKGROUND: The purpose of this study was to reduce the incidence of radiation-induced toxicity in patients with early-stage oropharyngeal cancer, using highly conformal radiation techniques.
METHODS: Between 2000 and 2011, 167 patients with T1-3N0-3 oropharyngeal cancer were treated with 46-Gy intensity-modulated radiation therapy (IMRT) followed by 22-Gy brachytherapy boost. In patients with node-positive disease, neck dissection was performed.
RESULTS: The 5-year Kaplan-Meier estimates of local control, regional control, disease-free survival (DFS), and overall survival (OS) were 94%, 97%, 84%, and 72%, respectively. Feeding tubes were required in 26% of the patients. Grade ≥2 late xerostomia and dysphagia were 11% and 8%, respectively. Chemotherapy, tumor subsite, and bilateral neck irradiation correlate significantly with toxicity. Quality of life (QOL) scores deteriorate during and shortly after treatment but returned in all scales to baseline scores within 6 to 12 months, with the exception of xerostomia.
CONCLUSION: Brachytherapy boost and neck dissection (in node-positive oropharyngeal cancer) after 46-Gy of IMRT resulted in excellent outcomes with low incidence of late toxicity and good QOL scores.
Copyright © 2013 Wiley Periodicals, Inc., A Wiley Company.

Entities:  

Keywords:  IMRT; brachytherapy; oropharyngeal cancer; quality of life; toxicity

Mesh:

Year:  2013        PMID: 23483648     DOI: 10.1002/hed.23244

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

Review 1.  The humanistic burden of head and neck cancer: a systematic literature review.

Authors:  Erika Wissinger; Ingolf Griebsch; Juliane Lungershausen; Michael Byrnes; Karin Travers; Chris L Pashos
Journal:  Pharmacoeconomics       Date:  2014-12       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.